Heptares expands executive management team
With the appointment of Daniel Grau as president
Grau, who has been a senior advisor to Heptares focused on business development and corporate strategy since 2010, is based in Boston, MA, US and will have broad responsibilities for corporate and commercial development. He joins Heptares as it enters a new stage of growth and value creation, building upon a year of pipeline breakthroughs and corporate deals.
Focused on novel GPCR-targeted medicines, Heptares has assembled a pipeline of therapeutic agents for serious neurological (CNS) and metabolic disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, anxiety, chronic insomnia and type II diabetes. The firm has signed commercial partnerships with pharma companies such as Takeda, AstraZeneca, Shire and Novartis.
Malcolm Weir, Heptares’ chief executive commented: ‘As a key advisor to the company over the past year, Dan contributed significantly to our business development deals and to defining our pipeline strategy. His leadership in corporate and commercial development will be increasingly valuable as Heptares’ pipeline progresses and as partnerships organise around defined regions of GPCR target space.’
Grau is currently a member of the Product Advisory Board of Concert Pharmaceuticals. Previously he served as president and ceo of Cortria Corporation, chief operating officer of CombinatoRx (today Zalicus), and as a business consultant to Pharmacia Corporation (today Pfizer).
You may also like
Ingredients
Heptares and Jitsubo to develop novel GPCR-targeting peptide candidates for severe gastrointestinal disorders
Sosei Group announces that its subsidiaries, Heptares and Jitsubo Co., Ltd, and have entered into a collaboration to develop novel peptide candidates designed to target a G protein-coupled receptor (GPCR) implicated in severe gastrointestinal (GI) disorders
